RESEARCH MONOGRAPH · KDC-MN-070

Cortexin

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

38/100

Bovine cortical peptide cocktail that's basically impossible to characterize and very popular in Russia anyway

Cortexin is one of those Russian polypeptide preparations that's been clinically prescribed since the 80s with essentially zero hope of ever being properly characterized by western pharmacology standards. The product is a low-molecular-weight peptide fraction (under 10 kDa) extracted from bovine cerebral cortex, and the indications are everything you'd expect from a Russian neurotrophic: stroke recovery, TBI, encephalopathy, pediatric developmental disorders, age-related cognitive decline.

The honest problem is that "cortexin" isnt one molecule. It's a mixture of probably 50+ short peptides plus amino acids plus some protein fragments, and the exact composition varies batch to batch because the source material (calf brain) is biological. Geropharm publishes some HPLC profiles but the active components are not definitively identified, despite decades of clinical use.

What we like: the idea that cortical peptide hydrolysates contain bioactive sequences is not crazy. Some of the peptides that have been identified (a few resemble fragments of myelin basic protein, synapsin, and various neurotrophic factor precursors) could plausibly do something. Pavlov Medical University has published on individual fractions showing some neuroprotective activity in cell culture.

What we dont like: you cant really validate a mixture this complex with normal pharmacological methods. The clinical trials are all open-label or sketchy-blinded, the effect sizes vary wildly across indications, and theres no plausible pharmacokinetics story because most of these peptides shouldnt survive parenteral injection intact for very long. The mechanism claims (neurotrophic, antioxidant, GABAergic, glutamate modulation) read like a checklist of every favorable thing you could say about a CNS drug.

Sourcing is the big problem. Even reputable Russian manufacturers cant give you batch-to-batch consistency the way you'd get with a defined peptide, and western synthetic alternatives essentially dont exist because nobody can specify what to synthesize.

Honestly, this is a category-of-product, not a defined compound, and we cant get to much research enthusiasm. If you want to study brain-derived peptide fractions, fine, but treat it as a hydrolysate, not a drug. The evidence base just isn't there.

Evidence: 25
Mechanism: 30
Reliability: 35
Safety: 70
Sourcing: 30
Value: 40
Signal: 40
Staying power: 30

Plain-language summary Intrigue 52 / 100

Cortexin is a Russian-developed bovine cortex peptide hydrolysate, similar in concept to cerebrolysin but from cerebral cortex tissue rather than whole brain. Used in Russia for stroke and cognitive impairment. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Bovine cortex peptide hydrolysate

A Russian peptide preparation from bovine cerebral cortex used parenterally for cognitive impairment and acute neurological events.

Abstract

Cortexin is a peptide hydrolysate prepared from bovine cerebral cortex, manufactured by Geropharm (Russia) and approved in Russia and several former Soviet states for cognitive impairment of vascular and post-traumatic origin, perinatal encephalopathy, cerebral palsy, epilepsy adjunct, and acute stroke. The product contains low-molecular-weight peptides and amino acids in a complex mixture; biological activity is attributed primarily to the peptide fraction. Mechanism is incompletely characterized; proposed activities include neurotrophic factor mimetic effects, antioxidant activity, and modulation of glutamate-mediated excitotoxicity. The product is administered by intramuscular injection. Pharmacokinetics are difficult to characterize given the complex active substance composition. Reported research dose ranges in the literature are described in the source monograph. The Russian clinical literature is substantial but Western-grade randomized trials are limited.

Mechanism of action

Complex bovine cortex peptide mixture; presumed neurotrophic and antioxidant effects.

Reported research dose ranges

10 to 20 mg IM in the literature.

References

Ryabukhin IA, et al. Cortexin clinical pharmacology. Russian neurological literature.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-070

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Cortexin

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs